Moreover, we investigated whether this scFv-anti-LDL(-)-MCMN-Zn nanoformulation inhibits the progression of atherosclerosis in Ldlr−/− mice, evaluating its promising use in drug delivery and as a targeting approaches to prevention and treat the progression of atherosclerosis. This evidence concerns the gene LDLR and atherosclerosis.